Glioma Stemlike Cells Enhance the Killing of Glioma Differentiated Cells by Cytotoxic Lymphocytes.
-
Bassoy EY
Department of Cell Physiology and Metabolism University of Geneva, 1211, Geneva, Switzerland.
-
Chiusolo V
Department of Cell Physiology and Metabolism University of Geneva, 1211, Geneva, Switzerland.
-
Jacquemin G
Department of Cell Physiology and Metabolism University of Geneva, 1211, Geneva, Switzerland.
-
Riccadonna C
Geneva University Hospitals and University of Geneva, Centre of Oncology, 1211, Geneva, Switzerland.
-
Walker PR
Geneva University Hospitals and University of Geneva, Centre of Oncology, 1211, Geneva, Switzerland.
-
Martinvalet D
Department of Cell Physiology and Metabolism University of Geneva, 1211, Geneva, Switzerland.
Show more…
English
Glioblastoma multiforme, the most aggressive primary brain tumor, is maintained by a subpopulation of glioma cells with self-renewal properties that are able to recapitulate the entire tumor even after surgical resection or chemo-radiotherapy. This typifies the vast heterogeneity of this tumor with the two extremes represented on one end by the glioma stemlike cells (GSC) and on the other by the glioma differentiated cells (GDC). Interestingly, GSC are more sensitive to immune effector cells than the GDC counterpart. However, how GSC impact on the killing on the GDC and vice versa is not clear. Using a newly developed cytotoxicity assay allowing to simultaneously monitor cytotoxic lymphocytes-mediated killing of GSC and GDC, we found that although GSC were always better killed and that their presence enhanced the killing of GDC. In contrast, an excess of GDC had a mild protective effect on the killing of GSC, depending on the CTL type. Overall, our results suggest that during combination therapy, immunotherapy would be the most effective after prior treatment with conventional therapies.
-
Language
-
-
Open access status
-
gold
-
Identifiers
-
-
Persistent URL
-
https://sonar.ch/global/documents/76327
Statistics
Document views: 21
File downloads: